Search results for "Venous thromboembolism"
MKSAP Quiz: 2-year history of worsening hot flashes
A 56-year-old woman is evaluated for a 2-year history of worsening hot flashes and night sweats. She reports that the night sweats awaken her several times nightly, resulting in fatigue and missed work. Following a physical exam, what is the most appropriate treatment?
https://immattersacp.org/weekly/archives/2022/12/20/3.htm
20 Dec 2022
New warning for testosterone, approval for inhaled insulin
This update covers a revised warning on testosterone products about the risk of venous thromboembolism, and approval of a fast-acting inhaled insulin to treat diabetes in adults.
https://immattersacp.org/archives/2014/09/fda.htm
1 Sep 2014
Warfarin-aspirin therapy associated with increased bleeding compared with warfarin only
Patients with atrial fibrillation or venous thromboembolism who received aspirin without a clear therapeutic indication in addition to warfarin had higher rates of bleeding and similar rates of thrombosis.
https://immattersacp.org/weekly/archives/2019/03/12/2.htm
12 Mar 2019
Tailoring anticoagulation more of a reality with DOACs
Direct oral anticoagulants have the potential to replace warfarin for the treatment of many patients with venous thromboembolism, but without a need for routine monitoring, good patient selection is key to their use.
https://immattersacp.org/archives/2018/03/tailoring-anticoagulation-more-of-a-reality-with-doacs.htm
1 Mar 2018
MKSAP Quiz: Evaluation for β-thalassemia intermedia
A 35-year-old man is evaluated during a routine visit for β-thalassemia intermedia. One year ago, he began requiring erythrocyte transfusions every 4 to 6 months for symptomatic anemia. He has no other symptoms or medical problems, and his only medication is folic acid. Following a physical exam and lab studies, what is the most appropriate additional management?
https://immattersacp.org/weekly/archives/2023/09/12/3.htm
12 Sep 2023
Industry-funded trial finds a direct factor X inhibitor noninferior to a low-molecular-weight heparin for cancer-associated VTE
Edoxaban was associated with a lower rate of recurrent venous thromboembolism (VTE) but a higher rate of major bleeding.
https://immattersacp.org/weekly/archives/2017/12/19/2.htm
19 Dec 2017
VTE risk appears lower with transdermal vs. oral hormone replacement therapy
Nested case-control studies using two U.K. primary care databases found that oral hormone replacement therapy was associated with a significantly increased risk for venous thromboembolism (VTE), while transdermal formulations were not.
https://immattersacp.org/weekly/archives/2019/01/15/1.htm
15 Jan 2019
New guidelines aim to improve diverticulitis treatment
This issue includes stories on managing diverticulitis, using direct oral anticoagulants, and payment and performance measures.
https://immattersacp.org/archives/2022/04/new-guidelines-aim-to-improve-diverticulitis-treatment.htm
1 Apr 2022
Outcomes of limited cancer screening after unprovoked VTE similar to extensive screening
The overall prevalence of cancer in the 12 months after a diagnosis of venous thromboembolism was 5.2%. While the point prevalence was higher in patients receiving extensive screening than in those receiving limited screening, there was no significant difference at one year.
https://immattersacp.org/weekly/archives/2017/08/22/4.htm
22 Aug 2017
Special Focus: Diagnosing Pulmonary Embolism
Evidence-based recommendations about care.
https://immattersacp.org/archives/2008/01/special.htm
1 Jan 2008